Open an account

Nexalin Technology

NXL · NASDAQ

$2.14−$0.22 (−9.32%)TodayMarket closed ·
Prev close $2.36

About NXL

Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Employees
8
Headquarters
Houston, Texas
Listed
Sep 16, 2022
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
nexalin.com

NXL key statistics

Market cap
2.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.25M
Volume
248.28K
Open price
$2.52
High today
$2.54
Low today
$2.12
52 Week high
$50.70
52 Week low
$2.10

Nexalin Technology (NXL) at a glance

As of Oct 20, 2026, Nexalin Technology (NXL) shares are priced at $2.14, giving the company a market cap of 2.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.12 and $2.54. The current price is 0.9% above the day's low and 15.7% below its high.

Volume so far is 248.28K shares, below the average of 3.25M shares a day.

Over the past year Nexalin Technology has ranged from $2.10 to $50.70, and now sits 0% of the way up that range.

Nexalin Technology met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$3.30 per share against an estimate of -$3.03.

NXL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 29.3% on average.

  1. Q3 FY24: reported -$6.90 per share against an estimate of -$3.64
  2. Q4 FY24: reported -$8.40 per share against an estimate of -$3.64
  3. Q1 FY25: reported -$4.50 per share against an estimate of -$3.03
  4. Q2 FY25: reported -$3.00 per share against an estimate of -$4.24
  5. Q3 FY25: reported -$3.90 per share against an estimate of -$3.64
  6. Q4 FY25: reported -$3.81 per share against an estimate of -$3.64
  7. Q1 FY26: reported -$3.30 per share against an estimate of -$3.03
  8. Q2 FY26: reported -$3.30 per share against an estimate of -$3.03

NXL news

  • Avi Kapoor

    Dow Jumps Over 300 Points; US Economy Adds 29,000 Jobs In September

  • Avi Kapoor

    Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September

  • Vandana Singh

    Why Is Nexalin Technology Stock Gaining Thursday?

  • Press releaseGlobe Newswire

    These Stocks Roar into October with Fresh Catalysts

  • Avi Kapoor

    Dow Falls Over 200 Points; Micron Earnings Top Views

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Akanksha Bakshi

    EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life

  • Vandana Singh

    EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Similar companies

Companies in the same industry as Nexalin Technology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.